The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Rahul BanerjeeDuring the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Rahul Banerjee, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, What is the impact of dexamethasone dose strength on outcomes in newly diagnosed multiple myeloma?
What is the impact of dexamethasone dose strength on outcomes in NDMM?
Banerjee discusses the toxicity profile of dexamethasone in patients with newly diagnosed multiple myeloma treated with a standard dose of ~40 mg weekly. He then explores the impact of reducing dexamethasone dose strength on incidence and patient outcomes, highlighting both the frequency of adverse events and differences in efficacy outcomes. He concludes by explaining the implications of this data on future dexamethasone use and how to determine the optimal initial dose strength.